Lisa La on the Next Steps for a Study of Diabetes in Patients with Multiple Myeloma

Video

The director of clinical research in the Center for Cancer Care at White Plains Hospital spoke about what she intends to evaluate for a patient population with multiple myeloma and diabetes moving forward.

A study presented at the 2020 ASH Annual Meeting & Exposition aimed to evaluate differences in baseline characteristics, treatment patterns, and survival outcomes in diabetic versus nondiabetic patients enrolled in the CONNECT Multiple Myeloma Registry.

Ultimately, this study highlighted an unmet need of providing better supportive care for diabetes management in patients with multiple myeloma in order to further improve survival outcomes.

In an interview with CancerNetwork®, Lisa La, director of clinical research in the Center for Cancer Care at White Plains Hospital, discussed what are the next steps in store for the study and what areas of research she intends to explore moving forward.

Transcription:

[We] are in the process of looking at subgroup analyses of patients [receiving transplant]. Is there a difference in the utilization of it between the 2 groups, diabetics versus nondiabetics? Is transplant used equally in the 2 groups, or is there a big difference? As we know, transplant [leads to] better overall survival in patients with myeloma at first-line treatment, and so on and so forth. If diabetic patients aren’t given that opportunity because of some sort of comorbidities, they’re obviously going to be at a disadvantage and have shorter overall survival.

We know that just in general [in the United States] general population, non-Hispanics and African Americans have a higher prevalence of diabetes. How does that look for African American patients with [myeloma and] diabetes? Is it comparable to the US population? Is there a difference in their outcomes just within the group. [For] African Americans with diabetes, is there a difference [from] Hispanics. There are a lot of interesting things…specifically for race, [to determine] if there’s a difference in transplant.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content